OBJECTIVETo explore the influence of nonylphenol (NP) on the neural behavioral development of filial generation rats exposed via placenta.

METHODSOn the first day of the pregnancy, the SD rats were divided into four groups, and orally administered with NP at doses of 0, 50, 100 and 200 mg/kg on gestational day 9 approximately 15 respectively. The offspring rats of each groups were examined to observe the impact of NP on the early physiological, neurobehavioral development. The changes of filial generation body weight (from generation day 1 to 28) were measured. Brain tissues were stained with Hematoxylin-eosin and Congo red to observe with optical microscope.

RESULTSIn contrast to the control group, the early physiological markers (pinna detachment, hair growth, tooth growth and eye opening) and the early neurobehavioral development indices (surface righting, air righting, acoustic startle and visual placing) were significantly delayed in the groups of NP 200mg/kg dose (P < 0.05). The developing time of physiological markers decreased from (4.5 +/- 0.8, 5.2 +/- 0.8, 12.7 +/- 1.4, 16.0 +/- 1.7) d to (3.6 +/- 0.5, 3.6 +/- 0.5, 11.1 +/- 1.1, 12.7 +/- 1.3) d while neurobehavioral developing time decreased from (6.5 +/- 0.8, 11.3 +/- 0.5, 11.2 +/- 1.0, 20.2 +/- 1.0) d to (5.1 +/- 0.4, 8.3 +/- 0.5, 9.3 +/- 0.5, 9.3 +/- 0.5) d (P < 0.05 or P < 0.01). The body weights of filial generation rats were decreased obviously from 1 st day to 28th day. Histopathological examination displayed that hippocampal neurons had congestion and oedema in the group of 100, 200 mg/kg dose.

CONCLUSIONExposures to NP during gestation might impair the neurobehavioral development of F1 rats significantly.

Animals ; Female ; Hippocampus ; pathology ; Phenols ; toxicity ; Placenta ; drug effects ; Pregnancy ; Prenatal Exposure Delayed Effects ; physiopathology ; Rats ; Rats, Sprague-Dawley

OBJECTIVETo evaluate the efficacy and analyze the prognostic factors of sorafenib treatment in patient with unresectable primary hepatocellular carcinoma (HCC).

METHODSDuring the period from December 2005 to March 2009, 50 patients with unresectable primary HCC of Child-Pugh status A were treated with sorafenib (400 mg, Bid). The tumor response was evaluated with CT or MRI imaging every 6 - 8 weeks according to the RECIST criteria. The overall survival (OS) and time to progression (TTP) were defined as the time from administration of sorafenib to the death or the last follow up and were evaluated by Kaplan-Meier method.

RESULTSThere was no PR or CR, but 28 patients (56.0%) achieved stable disease. The median follow up time was 15 months with a median OS of 14 months and median TTP of 4 months. The common adverse events were dermal reaction (68.0%, 34/50), diarrhea (52.0%, 26/50), hypertension (4.0%, 2/50), hair loss (14.0%, 7/50), myelosuppression (16.0%, 8/50), and liver dysfunction (20.0%, 10/50). However, most of the drug-related adverse events were grade I-II and reversible. The patients with lower tumor burden and without distant metastasis had better prognosis.

CONCLUSIONSoafenib is effective for unresectable primary HCC with tolerable toxicity. Tumor stage is a predominant prognostic factor.

Adult ; Aged ; Alopecia ; chemically induced ; Antineoplastic Agents ; adverse effects ; therapeutic use ; Benzenesulfonates ; adverse effects ; therapeutic use ; Carcinoma, Hepatocellular ; drug therapy ; Chemoembolization, Therapeutic ; methods ; Diarrhea ; chemically induced ; Disease Progression ; Follow-Up Studies ; Humans ; Hypertension ; chemically induced ; Liver Neoplasms ; drug therapy ; Male ; Middle Aged ; Neoplasm Staging ; Niacinamide ; analogs & derivatives ; Phenylurea Compounds ; Pyridines ; adverse effects ; therapeutic use ; Skin Diseases ; chemically induced ; Survival Rate

Objective To analyze etiology of hospitalized hypertensive patients in the department of hypertension from 1999 to 2008. Methods This retrospective study was performed to analyze the etiology of hospitalized hypertensive patients in department of hypertension and to show the distribution change of hypertension from 1999 to 2008. Results ( 1 ) There were 5867 ( 75. 1% ) patients with essential hypertension and 1942 (24. 9% ) patients with secondary hypertension (SH). (2) The prevalence rate of SH increased significantly during the 10 years (χ2 = 387.621 ,P ＜ 0.001 ) and was higher in 2008 than in 1999 (39. 3% vs. 9. 5% , P ＜ 0. 05 ). The prevalence of obstructive sleep apnea syndrome (OSAS) and primary aldosteronism (PA) in 2008 increased 38.3 and 1.8 times respectively than in 1999 (χ2 =304. 025 ,P ＜0. 001; χ2 =42. 845 ,P ＜0. 001 ) and other SH remained unchanged. ( 3 ) The prevalence of PA complicated with OSAS increased significantly in recent five years ( χ2 = 26.376, P ＜0. 001 ). Incidence of OSAS was 23.9% in PA patients and incidence of PA was 6. 7% in OSAS patients. Conclusions With the insights gained on hypertension mechanism and the development of new diagnostic technology, percent of diagnosed SH increased remarkably in recent years in hospitalized hypertensive patients in our department of hypertension. OSAS and PA are the leading causes of SH.

OBJECTIVETo investigate the expression level of S100A6 mRNA in MM and to its clinical significance, and to evaluate its significance.

METHODSThe expression level of S100A6 mRNA in MM patients was determined by real time quantitative PCR(RQ-PCR), and its relationship with the clinical features and outcomes of patients was analyzed by statistic method.

RESULTSS100A6 mRNA was detected in 20 MM patients. Compared with normal persons, the S100A6 mRNA expression in MM patients was higher. In different groups, the S100A6 mRNA expression in MM patients of 3 stages was higer than that in patients of 1 and 2 stages. MM patients with higher S100A6 mRNA expression had poor prognosis and higer extramedullary metastasis rate.

CONCLUSIONThe high expression of S100A6 mRNA is associated with poor prognosis and may be a prognostic molecular marker of MM.